Irvine, CA - Rubicon Biotechnology LLC is pleased to announce a grant award from the US Army Medical Research & Development Command (USAMRDC) to study Rubicon’s Rapid Recovery technology in ocular cytoprotection. The project, titled “Rapid Delivery of Hsp72 for Ocular Cytoprotection After a Traumatic Brain Injury” is supported by the Assistant Secretary of Defense…
Read more
Rubicon Awarded Traumatic Brain Injury Grant from USAMRDC
Irvine, CA - Rubicon Biotechnology LLC is pleased to announce an award from the US Army Medical Research & Development Command (USAMRDC) to study Rubicon’s Rapid Recovery technology in traumatic brain injury (TBI). The 3-year study titled, "Intracellular Delivery of Hsp72 for Neural Cytoprotection After Traumatic Brain Injury”, includes the optimization and characterization of the…
Read more
Rubicon Selects Celltheon Expression Technologies for Fv-Hsp72
Irvine, CA - Rubicon Biotechnology LLC is pleased to announce the selection of Celltheon Expression Technologies for cell line, process, and analytical development services in support of Rubicon’s Fv-Hsp72 program. The program includes the expression and screening of several variants, with the winning variants proceeding to further cell line development utilizing Celltheon’s SMARTTM Platform. The…
Read more
Rubicon Announces National Eye Institute Grant
Lake Forest, CA - Rubicon Biotechnology, LLC is pleased to announce that it was awarded a SBIR Phase I grant by the National Eye Institute titled “Targeted Hsp72 as a Therapeutic for Central Retinal Artery Occlusion”. Rubicon is collaborating with Drs. Michael Gorin and Anna Matynia and their teams at the Stein Eye Institute at…
Read more
- 1
- 2